American Surgical Association
130th Annual Meeting Abstracts

Back to Program Outline

HuR Status Is A Powerful Marker For Prognosis And Response To Chemotherapy For Resected Pancreatic Ductal Adenocarcinoma Patients.
*Nathan G Richards, *Agnes K Witkiewicz, *Christina L Costantino, *Dane R Grenda, *David W Rittenhouse, *Eugene P Kennedy, *Jonathan R Brody, Charles J Yeo
Thomas Jefferson University, Philadelphia, PA

OBJECTIVE(S): Treatment of pancreatic ductal adenocarcinoma (PDA) typically includes chemotherapy with gemcitabine. No reliable biomarker exists for overall prognosis or response to chemotherapy. Two previously proposed prognostic markers, COX-2 and VEGF, are regulated by HuR, an mRNA binding protein that we have demonstrated to be a promising predictive marker of gemcitabine response (Cancer Research 2009, 69:4567-72). This study was designed to evaluate a clinically useful biomarker for PDA.
METHODS: A tissue microarray of specimens including 53 with PDA, who underwent potentially curative resection, was analyzed. HuR, COX-2, and VEGF status were correlated with clinical data and compared for relative utility.
RESULTS: Roughly 50% (27/53) of patients had elevated cytoplasmic HuR expression (HuR+). These patients had worse pathologic features (i.e. positive lymph nodes (75%) and AJCC pathologic stage 2 or greater (94%)) compared to HuR- patients. Cytoplasmic HuR status correlated with staging better than VEGF or COX-2 expression alone. When used in combination, HuR cellular positivity with VEGF+ status yielded 100% lymph node positivity. Additionally, HuR status was an unprecedented positive predictive marker for overall survival in patients treated with gemcitabine pushing median survival over 40 months in the HuR+ patient population (p-value 0.0049).
CONCLUSIONS: HuR status is a robust predictor of outcome for patients with resected PDA. This study supports the notion that HuR should be used by clinicians for the individualized treatment for PDA.


Back to Program Outline